OSU-03012, a non-cox inhibiting celecoxib derivative, induces apoptosis of human esophageal carcinoma cells through a p53/Bax/cytochrome c/caspase-9-dependent pathway

Anti-Cancer Drugs

Volumn 24, Issue 7, 2013, Pages 690-698

  Liu, Juan ^a   Qin, Cheng Kun ^a   Lv, Wei ^a   Zhao, Qi ^a   Qin, Cheng Yong ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

apoptosis; esophageal carcinoma; mitochondrial pathway; OSU 03012

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; CASPASE 3; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE 9 INHIBITOR; CYTOCHROME C; DNA NUCLEOTIDYLEXOTRANSFERASE; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; Z IETDFMK; Z LEHDFMK;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DISEASE DURATION; DOWN REGULATION; DRUG CYTOTOXICITY; ESOPHAGUS CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 9; CELL LINE, TUMOR; CYTOCHROMES C; ESOPHAGEAL NEOPLASMS; HUMANS; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879953293     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328362469f     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002 featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97:1407-1427.
3. Johnson AJ, Smith LL, Zhu J. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase-and Bcl-2-independent mechanism. Blood 2005; 105:2504-2509.
4. Yacoub A, Park MA, Hanna D. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006; 70:589-603.
5. McCubrey JA, Lahair MM, Franklin RA. OSU-03012 in the treatment of glioblastoma. Mol Pharmacol 2006; 70:437-439.
6. Kucab JE, Lee C, Chen CS. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005; 7:R796-R807.
7. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006; 10:207-214.
8. Zhu J, Huang JW, Tseng PH. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004; 64:4309-4318.
9. Zhang S, Suvannasankha A, Crean CD. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clinical Cancer Res 2007; 13:4750-4758.
10. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603-2614.
11. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003; 195:158-167.
12. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-776.
13. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39:615-647.
14. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Eksborg S, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008; 27:2910-2922.
15. Jianmin Z, Hongfang W, Meifu F. Resistance of multicellular aggregates to pharmorubicin observed in human hepatocarcinoma cells. Braz J Med Biol Res 2002; 35:255-260.
16. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5, 5, 6, 6-tetrachloro-1, 1, 3, 3-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993; 197:40-45.
17. Liu H, Qin C-K, Han G-Q. Synthetic chenodeoxycholic acid derivative, HS-1200, induces apoptosis of human hepatoma cells via a mitochondrial pathway. Cancer Lett 2008; 270:242-249.
18. Oh M, Chung HY, Kim KW, Kim SI, Kim DK. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 1999; 14:69-875.
19. Nagaraj N S, Anilakumar K R, Singh O V. Diallyl disulfide causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway. J Nutr Biochem 2010; 21:405-412.
20. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003; 17: 1547-1549.
21. Jendrossek V, Muller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 2003; 22: 2621-2631.
22. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000; 19:4563-4573.
23. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001; 97:1378-1387.
24. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285:1733-1737.
25. Shen ZY, Shen WY, Chen MH, Shen J, Cai WJ, Zeng Y. Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3. Int J Mol Med 2002; 9:385-390.
26. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol Lett 2004; 149:19-23.
27. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281:1312-1316.
28. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999; 274:20049-20052.
29. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15:269-290.
30. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308.
31. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305:626-629.
32. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
33. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397:441-446.
34. Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 2007; 20:01-22.
35. Xu GW, Shi YF. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res 2007; 17:759-771.
36. Zou H, Li X, Wang X. An Apaf-1, cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274:11549-11556.
37. Renz A, Berdel WE, Kreuter M, Belka C, Schulze-Osthoff K, Los M. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 2001; 98:1542-1548.
38. He J, Xiao Y, Casiano CA, Zhang L. Role of mitochondrial cytochrome c in cocaine-induced apoptosis in coronary artery endothelial cells. J Pharmacol Exp Ther 2000; 295:896-903.
39. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95:4997-5002.
40. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998; 391:496-499.
41. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000; 7:1182-1191.
42. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 1999; 274:32580-32587.
43. Salomons GS, Brady HJ, Verwijs-Janssen M, Van Den Berg JD, Hart AA, Van Den Berg H. The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 1997; 71:959-965.
44. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. The p53 circuit board. Biochim Biophys Acta 2012; 1825:229-244.
45. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-208.
46. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-206.
47. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is an ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-27.
48. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ 2006; 13:1256-1259.
49. Yang R, Hao J, Wang J, Sun C, Fesik SW, Wu JC, et al. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem 2003; 278:8091-8098.